Bucillamine: Interim Phase IIa data

Interim data from 29 patients with acute gout flares in an open-label, U.S. Phase IIa trial showed that once-daily 900 and 1,800 mg oral REV-002 for 7 days led to a >=50% reduction in target joint pai...